Nomogram to predict the outcomes of patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors

• Chiara Cremolini,
• Giovanni Fucà,
• Sara Lonardi,
• Federica Morano,
• Francesca Corti,
• Giuseppe Curigliano,
• Michael Overman,
• Elisabetta Fenocchio,
• Massimiliano Salati,
• Margherita Ambrosini,
• Lisa Salvatore,
• Rossana Intini,
• Priya Jayachandran,
• Javier Ros,
• Gabriele Infante,
• Maria Elena Elez,
• Marwan Fakih,
• Aakash Tushar Shah,
• Floriana Nappo,
• Silvia Damian,
• Rosalba Miceli

Affiliations

Chiara Cremolini

Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana; Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy

Giovanni Fucà

Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

Sara Lonardi

Medical Oncology 3, Istituto Oncologico Veneto IOV-IRCSS, Padua, Italy

Federica Morano

Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

Francesca Corti

Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

Giuseppe Curigliano

European Institute of Oncology (IEO), IRCCS, Milan, Italy; Department of Oncology and Hemato-oncology, University of Milan, Milan, Italy

Michael Overman

Department of Gastrointestinal Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Elisabetta Fenocchio

Multidisciplinary Outpatient Oncology Clinic, Candiolo Cancer Institute FPO-IRCCS, Candiolo, Italy

Massimiliano Salati

Division of Oncology, Department of Oncology and Hematology, University Hospital of Modena, PhD Clinical and Experimental Medicine (CEM), University of Modena and Reggio Emilia, Modena, Italy

Margherita Ambrosini

Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

Lisa Salvatore

Department of Medical Oncology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy

Rossana Intini

Medical Oncology 1, Istituto Oncologico Veneto IOV-IRCCS, Padua, Italy

Priya Jayachandran

Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, California, USA

Javier Ros

Department of Medical Oncology, Vall d`Hebron Barcelona Hospital Campus, Vall d`Hebron Institute of Oncology (VHIO), Universitat Autonoma de Barcelona, Barcelona, Spain

Gabriele Infante

Unit of Clinical Epidemiology and Trial Organization, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

Maria Elena Elez

Department of Medical Oncology, Vall d`Hebron Barcelona Hospital Campus, Vall d`Hebron Institute of Oncology (VHIO), Universitat Autonoma de Barcelona, Barcelona, Spain

Marwan Fakih

Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, California, USA

Aakash Tushar Shah

Baylor College of Medicine, Houston, Texas, USA

Floriana Nappo

Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy

Silvia Damian

Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

Rosalba Miceli

Unit of Clinical Epidemiology and Trial Organization, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy